Compare stocks

NBTX vs SPRY

Nanobiotix S.A. American Depositary Shares and ARS Pharmaceuticals, Inc. Common Stock

Compare the businesses

Nanobiotix S.A. American Depositary Shares

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Open NBTX dashboard ↗

ARS Pharmaceuticals, Inc. Common Stock

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

Open SPRY dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗